Sheffield cell therapy spinout Rinri secured corporate backing from Boehringer Ingelheim and UCB in a seed round that will drive work on stem cell-based treatments for hearing loss.

OSF Healthcare Ventures was among the participants in an extension to the cancer testing technology provider's series B round, which has now reached $15m.

SinoUnited secured $14.4m and the Kuok Group-backed round will support the hiring of more doctors and the opening of additional healthcare centres.

M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.

Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.

The Parkwalk-managed co-investment fund has supplied Cambridge cancer therapy spinout PolyProx Therapeutics with capital, augmenting a $4.4m seed round for the latter announced earlier this month.

Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.

Medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.

Cambridge's cancer drug spinout Storm Therapeutics convinced its existing investors to join new participant Seroba Life Sciences for a second extension that brought its series A total to $38.2m.

HCSC Ventures led the disease prevention platform's series C round, investing alongside Blue Cross Blue Shield Venture Partners.